Related Experiment Video

Updated: Nov 3, 2025

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.7K

Secondary cytoreduction for relapsed ovarian cancer

Pankaj Kumar Garg1, Rahul Kumar1, Deepti Choudhary2

  • 1Department of Surgical Oncology, All India Institute of Medical Sciences, Rishikesh 249203, India.

The Lancet. Oncology
|June 4, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K
Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
05:58

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Published on: February 4, 2014

13.7K

Related Experiment Videos

Last Updated: Nov 3, 2025

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.7K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K
Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
05:58

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Published on: February 4, 2014

13.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

The Long Memory of Surgical Complications: A Reflection on Patients, Surgeons, and Healing.

The American surgeon·2026

Correction to: Development of a Competency-Based Curriculum for Surgical Oncology Training in India.

Indian journal of surgical oncology·2026

ABSI 2025 Consensus Guidelines on the Management of Breast Cancer in Low- and Middle-Income Countries.

Indian journal of surgical oncology·2026

Development of a Competency-Based Curriculum for Surgical Oncology Training in India.

Indian journal of surgical oncology·2026

Cancer screening uptake and tobacco-alcohol use among women in Uttarakhand: A district-wise analysis from the 5th National Family Health Survey (NFHS-5).

The Indian journal of medical research·2026

Cancer Patterns and Challenges in the Garhwal Region of Uttarakhand: A Hospital-Based Study.

Indian journal of surgical oncology·2026

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

The Lancet. Oncology·2026

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

The Lancet. Oncology·2026

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

The Lancet. Oncology·2026

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

The Lancet. Oncology·2026

High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

The Lancet. Oncology·2026

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

The Lancet. Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us